Aims: The UK has a socialized healthcare system that provides treatment that is free at the point of care for acute and chronic health disorders (the National Health Service-NHS), which is currently experiencing a period of unprecedented challenge. Methods: A narrative review that discusses present and future arrangements for transplantation of alcohol-related liver disease (ArLD) in the UK. Results: Liver disease in the UK is reaching epidemic proportions due to obesity and metabolic disease compounding alcohol-mediated liver damage. Unfortunately, hepatology services in the UK are geographically disparate and subject to significant variations in liver morbidity and mortality, prompting concerns that this may negatively impair access to transplantation. In an attempt to improve referrals to tertiary liver services, the UK listing criteria for alcohol-associated liver disease were revised in 2016 by a working party under the aegis of the UK-Liver Advisory Group with the ambition of increasing opportunities for disease evaluation and improving the condition of candidates referred for assessment. Conclusion: Liver transplantation for ArLD is well established in the UK. Recent organizational changes seek to reduce inequities in access to transplant services. Short Summary: Liver disease in the UK is reaching epidemic proportions. Concerns over equity of access to liver transplantation prompted revision of the UK listing criteria for alcohol-associated liver disease in 2016, to improve to the availability of tertiary hepatology services.
INTRODUCTION
The UK has a socialized healthcare system that provides free at the point-of-care treatment for acute and chronic health disorders (the National Health Service-NHS), which is currently experiencing a period of unprecedented challenge. Liver disease in the UK is reaching epidemic proportions due to obesity and metabolic disease compounding alcohol-mediated liver damage. Unfortunately, Hepatology services in the UK are geographically disparate and subject to significant variations in liver morbidity and mortality, prompting concerns that may negatively impair access to transplantation. In an attempt to improve referrals to tertiary liver services the UK listing criteria for alcohol-associated liver disease were revised in 2016 by a working party under the aegis of the UK-Liver Advisory Group (LAG) with the ambition of increasing opportunities for disease evaluation and improving the condition of candidates referred for assessment.
ALCOHOL-RELATED LIVER MORBIDITY IN ENGLAND
Nine million people in the UK regularly drink more than the daily recommended intake of alcohol and 2.5 million drink more alcohol in a single day than the recommended weekly allowance (Office for National Statistics (OFN), 2016). Statistics released by the charity Alcohol Concern suggest that harmful alcohol use causes 10% of the UK burden of disease and represents the second biggest cause of premature death after tobacco, (Alcohol Concern, 2017; Public Health England (PHE), 2017a) . In that context it is worrying that only 5% of the estimated 2.2 million individuals drinking at hazardous levels access treatment in the UK each year (PHE, 2014 (PHE, , 2017b (PHE, , 2017c .
Liver disease is the only major cause of mortality and morbidity that is increasing year on year in England, in contrast with cardiovascular disease, diabetes, and many forms of cancer. Over the last decade mortality rates from liver disease in the UK have risen by 40% and cirrhosis is now the third most common cause of premature death in the UK in adult males under the age of 65 (Murray et al., 2013) , (OFN, 2017) (Fig. 1) . Data from Public Health England indicates that almost 12,000 people died from chronic liver disease in 2014 (PHE, 2017a), most commonly due to harmful alcohol consumption. Moreover, 90% of liver deaths in the UK occur in individuals under 70 years of age, including 10% in adults under the age of 50 with an average age of death from alcohol-related liver disease (ARLD) in England of only 59 years (RightCare, 2013; National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 2013). Nearly all liver disease in the UK is preventable and caused by conditions such as alcohol, obesity or viral hepatitis, with less than 10% of cirrhosis being caused by autoimmune or genetic disease. Almost two in every three alcohol-related deaths are caused by liver disease in England.
Whilst there are a number of societal mores that govern the longstanding English association with heavy alcohol consumption (not least the fact that alcohol in the UK is now 61% more affordable than it was in 1980 (Health and Social Care Information Centre (HSCIC), 2016)), it is a fact that cirrhosis is a disease of inequality with a strong association between socio-economic deprivation and mortality from chronic liver disease (Fig. 2) . There is a marked geographical variation in the prevalence of alcohol-associated disease with people living in the most deprived quintile of England being three to five times more likely to die from alcohol-related liver disease than those living in the most affluent fifth (Department of Health (DoH), 2013). Within the UK poorer people are more likely to suffer ill health and are heavier users of healthcare resources than affluent individuals, but they present with illness at a more advanced stage whilst socially advantaged individuals present to healthcare providers earlier and are more likely to engage with preventive care (Cookson et al., 2016) . This is a point of concern as the NHS has limited resources for preventative care, particularly in relation to the availability of treatment for alcohol-use disorders. A national survey conducted by the charity Adfam in 2015 reported that a majority of community-based addiction services (38%) had received decreased funding over the preceding 12 months (Recovery Partnership, 2015) , and noted that an increasing proportion of funding targeted short term (12 weeks or less) projects rather than investing in long-term programmes that would provide sustainable service development: levels of disinvestment were even starker for residential addiction services.
HOSPITAL SERVICES FOR ALCOHOL-RELATED DISEASE IN ENGLAND
Many of the NHS services offered to patients afflicted with ARLD in the UK are inadequate. Liver disease accounts for 60% of inpatient gastroenterology activity in the UK and 25-30% of new outpatient referrals and yet only 15% of the total UK-gastroenterology workforce are trained as Hepatologists (British Society of Gastroenterology, 2017) . Of this small subgroup of consultants, one third are concentrated in the 7 UK liver transplant units, meaning that many district hospitals have limited experience in the management of chronic liver disease. The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) in 2013 (NCEPOD, 2013) audited the management of NHS patients who had been admitted and died from alcohol-related liver disease. Their influential report showed that, whilst 70% of district hospitals offered alcohol liaison services in working hours, only 11% offered the service at weekends and just 3% ran their services around the clock. Moreover, whilst half of patients died within 8 days of their arrival at hospital, 50% of those patients who did not see a GI or liver specialist at admission died within 3.5 days (NCEPOD, 2013). Many patients had already presented to healthcare providers in the preceding year with indications that would have ordinarily mandated consideration of liver replacement (for example 77% manifest ascites). Thus, the report highlighted a huge unmet need in UK-healthcare, illustrating the degree to which individuals with ARLD in the UK are often denied access to definitive and potentially life-saving therapies.
HEPATOLOGY SERVICES IN ENGLAND
Alcohol-related morbidity is ubiquitous with over 1.1 million NHS hospital admissions in 2014-2015 being related in some way to alcohol consumption (HSCIC, 2016) . Hospital episode statistics for the UK showed a 3% increase in admissions attributable to alcohol from 2013/14 to 2014/15, and a 32% increase over the previous decade. Despite this, significant inequalities exist in terms of the regional availability of hepatology services ( Fig. 3 ) especially considering the distribution of alcohol-related disease-mainly concentrated in the North West (Liverpool and Manchester) and the North East (Newcastle, Tyneside and Sunderland). Other pockets of high alcohol-related morbidity are seen in the urbanized West Midlands and it will come as no surprise that these regions contain some of the highest levels of socio-economic deprivation in Europe. By comparison, mortality from non-alcohol-related fatty liver disease (NAFL) is much more evenly distributed across the UK (Fig. 3) . The more affluent south-east of England has lower levels of liver disease and alcohol-related mortality than the rest of the country but possesses 3 of the 6 NHS-England funded liver transplant centres located within Central London and Cambridge. The poor distribution of NHS liver transplant centres across England allied with the associated neglect of liver services in regions with the highest rates of alcohol-related disease is one of the reasons that deaths from liver disease in the UK have reached record levels, rising by 20% in the last decade alone.
It is clear therefore that there are problems with equity of access to tertiary hepatology and liver transplant services in England with insufficient availability and provision of addiction services. Until these inequalities are properly addressed it seems that alcoholassociated disease will remain an major public health issue in the UK, costing the NHS in England around £3.5 bn each year and another £21 bn in the total societal costs attributable to alcoholrelated harm (PHE, 2014) .
TRANSPLANTATION FOR ALCOHOL-ASSOCIATED CIRRHOSIS IN THE UK
Whilst alcohol-associated liver disease is the commonest cause of cirrhosis in the UK, it was an uncommon indication for transplantation during the formative years of transplant programs both because of the perceived risk of alcohol lapse and negative public attitudes (Walsh and Alexander, 2000) . Times have changed and, whilst alcohol-related cirrhosis comprised only 6.9% of liver transplants per annum in Birmingham before the millennium (Bramhall et al., 2001) , alcohol-associated liver disease now comprises approx. 30% of current transplant activity and is expected to continue to rise. Given the transformation in viral hepatitis treatments it is probable that alcohol-associated disease will remain the largest single indication for transplantation in England by the end of the present decade.
LISTING CRITERIA FOR LIVER TRANSPLANTATION IN THE UK
Transplantation for alcohol-related liver disease (ArLD) is a viable and successful treatment option in carefully selected patients with end stage cirrhosis (OFN, 2017) , and accordingly the NHS provides this service through the seven liver transplant centres in the UK. Guidelines for the selection of transplant candidates with liver disease associated with previous alcohol-use disorders were first agreed within the UK in (Bathgate, 2006 . In 2015-2016 a working group of experts was commissioned to review the guidelines for selecting and listing patients with ArLD for transplantation and revise accordingly with the objective of improving inter-and intraunit consistency with regard to applying robust listing criteria (NCEPOD, 2013) (Williams et al., 2014) . The guidance aspires to improve the quality of referrals and requires referring centres to support their patients throughout the assessment process, although it continues to be an absolute requirement that patients referred for transplant assessment should not be actively consuming alcohol (National Institute for Health and Clinical Excellence (NICE), 2011). Descriptive terminology used to describe patterns of alcohol use has been improved (Table 1) in an effort to prevent alcohol-use disorders from becoming subordinate to other liver pathology (e.g. HCC, NASH or viral hepatitis) as all patients referred for liver transplantation, irrespective of their underlying disease, should be assessed for signs of alcohol and/or substance misuse due to the prevalence of alcohol-use disorders across the full diagnostic spectrum (Day et al., 2008) .
The previous UK referral system meant that otherwise suitable candidates could be made to wait in district hospitals for up to 6 months before being made known to transplant units, leading to patients being denied access to liver transplant assessment or coming to harm from delayed referral. This observation led to a revision of the recommendations for referral in the hope that patients will be made known to transplant centres at an earlier stage to enable preconditioning work and assessment to begin in good time (Table 2) .
It is still recommended that, wherever possible, individuals undergo a period of disease evaluation (arbitrarily defined as 3 months) prior to referral to a transplant unit where they receive optimal management of their clinical, nutritional and psychological needs in a setting local to the patient. It is important that the 3-month period of observation should be used profitably with intensive and ongoing support. This allows for assessment of their scope for clinical recovery and is envisaged as principally occurring within an outpatient setting. In order to provide corroborative evidence, abstinence should be biochemically validated wherever possible. The recommendations insist that patients should be actively supported by referring clinicians in establishing engagement with local addiction services and/or referral to specialist services/mutual aid support during and after transplant evaluation as there is growing evidence to suggest that this improves post-transplant sobriety (Erim et al., 2016; Heyes et al., 2016) . This period of evaluation is not mandatory: in cases where delays in referral might compromise outcome (e.g. where an individual also has a diagnosis of liver cancer), early psychosocial evaluation can be made and, if favourable, the individual may be listed if they are felt to be suitable for transplantation.
After referral, assessment for transplantation should occur in a multidisciplinary setting where specialists in addiction psychiatry and clinicians are co-located. The likelihood of relapse seems to be particularly strongly associated with the lack of robust social support networks, strong supportive friendships and/or the presence of a 'life-partner', and increased by factors such as psychological and/ or psychiatric co-morbidity. Allowing time to establish the framework of support around a transplant candidate is a vital component of transplant evaluation as it builds a relationship of trust, candour and honesty between the transplant centre and patient. A strong history of alcohol-use disorders or alcohol-centric behaviours within the wider family and/or co-habitation with individuals in a drinking environment are recognized points of concern, whilst the duration of abstinence (beyond periods of sickness that have required hospital admission) of more than 6 months remains a positive determinant of future behaviour, particularly for non-harmful alcohol consumption. The evidence increasingly supports the idea that specialist assessment is superior to time-based qualification in predicting the risk of alcohol relapse (Beresford and Everson, 2000) . Risk evaluation is Table 1 . Defining abstinence and alcohol-associated liver disease 1.1. Alcohol abstinence is defined as the avoidance of all alcohol containing drinks (including alcohol-free lagers and wines) or foods and a commitment to ongoing behavioural change to avoid triggers for relapse 1.2. Alcohol-related liver disease (ArLD) is defined as liver disease primarily due to sustained and harmful levels of alcohol consumption with or without a history of psychological or physical dependency 1.3. Alcohol-contributory liver disease (AcLD) occurs when alcohol has been consumed in a potentially harmful manner and is considered to have contributed to the resulting liver injury despite the fact that the primary insult to the liver may not be alcohol-related (e.g. HCV infection, HCC and/ or NASH). Such patients should be assessed and treated in the same way as patients with ArLD summative and no single point should rule a candidate out, but the reality is that it can be difficult to assess a patient's risk of alcohol relapse before transplantation due to factors such as hepatic encephalopathy, critical illness and organ failure and the limited time available for assessment. Under those circumstances the evaluation of a multidisciplinary team is the all important element in ensuring that good candidates for transplantation are not turned away and that individuals deemed to pose higher levels of risk are offered the support that they need. It is recognized that robust criteria for predicting a return to heavy drinking must discriminate consistently and be clinically meaningful, be objective, measurable and fair and cannot be, or unlikely to be, modified. It is also true that whilst alcohol relapse has a less noticeable effect in the first 5 years after transplantation (Pageaux et al., 1999; Mackie et al., 2001; Björnsson et al., 2005) by 10 years there is a clear difference between survival in liver transplant recipients who return to drinking and those who remain non-drinkers (Cuadrado et al., 2005; Pfitzmann et al., 2007) . The increase in late mortality noted in these studies is not related to alcohol-induced graft failure, but rather reflects increased rates of cardiovascular disease and solid organ malignancy (especially lung cancer and cancer of the upper gastrointestinal tract) and emphasizes the importance of ensuring long-term abstinence as graft function is not necessarily synonymous with patient outcome in individuals who reinstate alcohol-use post-transplant.
Absolute contraindications to liver transplantation include active alcohol use during the period of transplant evaluation and drinking alcohol on the waiting list. In addition, continued tobacco use (smoking) following assessment precludes surgery due to a growing recognition that smoking is associated with increased morbidity and mortality in liver transplant recipients (Leithead et al., 2008; Herrero et al., 2011) . Relative contraindications to liver transplantation include evidence of severe and enduring mental health problems that, in the opinion of the transplant team, might undermine the likelihood of a good clinical outcome and graft survival despite optimal psychiatric input. In addition, a history of cross dependency and/or episodes of alcohol lapse within 2 years despite clinical advice to abstain and in the knowledge of harm would be a significant cause for concern. The use of methadone replacement therapy is acceptable in conjunction with appropriate engagement with a prescriber/prescribing team. Individuals who are deemed to be at a particularly high risk of alcohol lapse should be evaluated in specialist clinics where their clinical and psychological needs can be met. We find it helpful to build dialogue with our patients before they are discussed in the listing meeting to facilitate bipartite understanding of the requirements and expectations associated with transplantation.
Within the UK acute Alcohol-induced Hepatitis (AAH) is not always an absolute contraindication to transplantation and patients who meet criteria for listing should be referred to participating centres for transplant evaluation where their suitability for surgery can be established.
CONCLUSIONS
Deaths from liver disease are rising in England and reflect the ubiquitous nature of alcohol-use disorders within society and the increasing prevalence of co-morbidities (obesity, diabetes, etc.) that amplify alcohol-associated liver injury in susceptible individuals. The perceived social stigma and lack of funding surrounding alcohol-related disease in the NHS means that investment in preventative services is slow and often inadequate leading to a dearth of addiction services, often in those areas with the highest clinical need. Moreover, there is a shortage of specialist clinical expertise in many district hospitals where mortality rates from alcohol-related liver disease can vary alarmingly (NCEPOD, 2013) .
Whilst alcohol-associated liver disease is rapidly becoming the single-most common indication for liver transplantation in the UK, it is still a sad fact that one in five individuals who die from alcoholrelated liver disease had five or more admissions to hospital in the year before their death and 70% of patients die from liver disease in an acute hospital bed (NCEPOD, 2013) . The clinical community must champion best practice wherever it is found and guidelines for transplant evaluation must complement these pathways to ensure that suitable candidates are not denied the opportunity for transplant assessment. It is vital that public confidence in the rigour of evaluation is maintained with an emphasis on multidisciplinary assessment and active ongoing management of the patient both before and after transplantation to ensure the best outcomes from organ replacement. Moreover, for those patients who are not deemed suitable for transplantation, expert palliation of the symptoms of advanced liver disease is just as vital a role as the clinical management of a patient on the transplant waiting list.
The new guidelines introduced in the UK look to do away with the unhelpful delays sometimes associated with proscriptive timebased qualification and focus instead on maintaining and improving patient condition in preparation for transplant evaluation. This positivity is an important part of patient care, where 'hope' remains a key message to instil in the patient journey as it possesses the means to empower an individual to take control of their life choices. By setting aspirational targets it is hoped that both the quality and quantity of referrals to transplant centres in the UK will increase, so that as many deserving individuals as possible will be offered the opportunity to benefit from transplantation.
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